Alagille syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Alagille syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effects-of-maralixibat-for-patients-with-alagille-syndrome/ Wed, 29 Apr 2026 15:04:39 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effects-of-maralixibat-for-patients-with-alagille-syndrome/ This clinical trial is focused on studying Alagille syndrome, a rare genetic disorder that affects the liver and other parts of the body. The study will use a treatment called Livmarli, which is an oral solution containing the active substance maralixibat. The purpose of the study is to evaluate how well patients tolerate the treatment, its long-term safety, and its effectiveness in managing symptoms of Alagille syndrome.

Participants in the study will take Livmarli as prescribed, and researchers will monitor them over an extended period. The study will look at various aspects, such as any side effects experienced, changes in liver function, and the severity of itching, which is a common symptom of the disease. The study will also observe how the treatment affects the levels of certain substances in the blood and the use of other medications for liver disease.

The trial aims to gather information on the safety of Livmarli over a long period, including any potential liver-related issues. It will also assess how well patients can tolerate the starting dose and any changes in dosage. The study will continue until 2035, providing valuable insights into the long-term management of Alagille syndrome with Livmarli.

]]> Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome https://clinicaltrials.eu/trial/long-term-study-on-the-safety-and-effectiveness-of-odevixibat-for-patients-with-alagille-syndrome/ Wed, 29 Apr 2026 14:57:13 +0000 https://clinicaltrials.eu/trial/long-term-study-on-the-safety-and-effectiveness-of-odevixibat-for-patients-with-alagille-syndrome/ This clinical trial is focused on studying the long-term safety and effectiveness of a medication called odevixibat (also known by its code name A4250) in patients with Alagille syndrome. Alagille syndrome is a genetic disorder that can affect the liver, heart, and other parts of the body, often leading to symptoms like severe itching. The purpose of this study is to see how well odevixibat works over an extended period and to ensure it is safe for patients to use.

The study involves two groups of patients. The first group includes patients who have already completed a previous study with odevixibat and will continue to take the medication to see if it helps with itching. The second group consists of younger patients, under 12 months old, who will be monitored to evaluate the safety and how well they tolerate the medication. Participants will take odevixibat in capsule form by mouth, and the study will last up to 72 weeks.

Throughout the study, researchers will observe changes in symptoms such as itching and scratching, as well as other factors like sleep quality and overall quality of life. The study aims to provide valuable information on how odevixibat can help manage symptoms of Alagille syndrome over a long period, contributing to better treatment options for those affected by this condition.

]]>